Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

(2017) Gabriel Etienne et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib

(2017) W Qiang et al.   LEUKEMIA

Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo

(2017) H Zhou et al.   LEUKEMIA

Current approach to the treatment of chronic myeloid leukaemia

(2017) Ivan Pasic et al.   LEUKEMIA RESEARCH

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

(2017) Andrew A. Wylie et al.   NATURE

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity

(2017) Cavan P. Bailey et al.   Oncotarget

Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing

(2017) Christopher T. Chen et al.   Journal of Oncology Practice

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

(2016) Philippe Rousselot et al.   CANCER

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

(2016) Yasufumi Matsuda et al.   CANCER SCIENCE

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

(2016) Sai Krishna Athuluri-Divakar et al.   CELL

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

(2016) A. K. Arun et al.   International Journal of Laboratory Hematology

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

(2016) Guillermo Garcia-Manero et al.   LANCET ONCOLOGY

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

(2016) Jeffrey H Lipton et al.   LANCET ONCOLOGY

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2016) Z Chen et al.   LEUKEMIA

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

(2016) Z Chen et al.   LEUKEMIA

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

(2016) David J. Dorer et al.   LEUKEMIA RESEARCH

Generic imatinib — impact on frontline and salvage therapy for CML

(2016) Larry Gorkin et al.   Nature Reviews Clinical Oncology

New investigational drugs with single-agent activity in multiple myeloma

(2016) A M Rajan et al.   Blood Cancer Journal

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

The impact of dasatinib on pregnancy outcomes

(2015) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

(2015) Rena M. Conti et al.   ANNALS OF HEMATOLOGY

Is there a best TKI for chronic phase CML?

(2015) R. A. Larson   BLOOD

Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors

(2015) J.H. Lipton et al.   LEUKEMIA RESEARCH

Allogeneic transplantation for CML in the TKI era: striking the right balance

(2015) Andrew J. Innes et al.   Nature Reviews Clinical Oncology

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells

(2015) Seiichi Okabe et al.   Oncotarget

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

(2015) Franck E Nicolini et al.   Lancet Haematology

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia

(2015) Houda Alachkar et al.   Oncotarget

Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

(2014) Tim H. Brümmendorf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells

(2014) Yue Yin et al.   LEUKEMIA & LYMPHOMA

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance

(2014) Zhiqiang Wang et al.   PLoS Genetics

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials

(2013) Yuan Ji et al.   JOURNAL OF CLINICAL ONCOLOGY

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

(2013) Concetta Quintarelli et al.   LEUKEMIA RESEARCH

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

(2013) Silvia Marcé et al.   MEDICINA CLINICA

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

(2013) L Qin et al.   Blood Cancer Journal

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

(2012) S. Luatti et al.   BLOOD

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Molecular Pathways: BCR-ABL

(2011) D. Cilloni et al.   CLINICAL CANCER RESEARCH

Inhibition of Ras for cancer treatment: the search continues

(2011) Antonio T Baines et al.   Future Medicinal Chemistry

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

(2010) Jorge Cortes et al.   CANCER

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

(2010) Dushyant Verma et al.   CANCER

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

(2010) B. D. Smith et al.   CLINICAL CANCER RESEARCH

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

(2010) B. J. Tunquist et al.   MOLECULAR CANCER THERAPEUTICS

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

(2009) D. Verma et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

(2009) D. Milojkovic et al.   CLINICAL CANCER RESEARCH

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD

Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells

(2007) Ichiro Nakano et al.   JOURNAL OF NEUROSCIENCE RESEARCH